The global postoperative nausea and vomiting (PONV) management market achieved a significant value of USD 1.04 billion in 2022 and is projected to grow substantially, reaching approximately USD 3.9 billion by 2033. This growth trajectory represents a robust CAGR of 12.8% during the forecast period from 2023 to 2033, underscoring the increasing focus on effective PONV management in surgical care.
The growth of the PONV management market can be attributed to several key factors, including the rising number of surgeries performed worldwide and the growing recognition of the importance of managing postoperative nausea and vomiting for enhancing patient comfort and safety. PONV is a common and distressing complication following surgery, often leading to prolonged recovery times and increased healthcare costs. As healthcare providers strive to improve patient experiences and outcomes, effective PONV management has become a critical focus area.
In the historical period from 2018 to 2022, the PONV management market registered a CAGR of 7.4%, reflecting a steady increase in awareness and advancements in treatment options. As new therapies and technologies continue to emerge, the market is well-positioned for significant expansion in the coming years, highlighting a commitment to improving postoperative care and patient satisfaction.
Postoperative nausea and vomiting (PONV) management refers to the various strategies and interventions used to prevent or treat nausea and vomiting in patients after surgery. PONV is a common side effect of anesthesia and surgery, affecting up to 80% of patients in some cases. It can cause discomfort, dehydration, electrolyte imbalances, and delayed recovery.
PONV management typically involves a combination of pharmacological and non-pharmacological interventions, such as antiemetic medications, IV fluids, and the use of acupressure or acupuncture. Effective PONV management is essential for patient comfort and recovery after surgery, and can also help prevent complications such as aspiration pneumonia and wound dehiscence.
2018 to 2022 Postoperative Nausea and Vomiting (PONV) Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Postoperative nausea and vomiting (PONV) management reflected a value of 7.4% during the historical period, 2018 to 2022.
The PONV management market has been growing steadily in recent years due to several factors, including an increasing number of surgeries being performed worldwide, growing awareness of the importance of PONV management for patient comfort and safety, and the development of new and effective antiemetic medications.
Several factors are driving the growth of the PONV management market, including the increasing prevalence of PONV, the development of new and effective antiemetic medications, and the adoption of non-pharmacological approaches to PONV management.
Thus, the market for postoperative nausea and vomiting (PONV) management is expected to register a CAGR of 12.8% in the forecast period 2023 to 2033.
Market Competition
Key players in the postoperative nausea and vomiting (PONV) management market are Acacia Pharma, Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline Corporation
- Acacia Pharma’s two primary antiemetic medications for PONV management are Barhemsys® and Amisulpride. Barhemsys® is a selective dopamine D2 and D3 receptor antagonist that is administered intravenously. The drug has been shown to be highly effective in the prevention and treatment of PONV and has received regulatory approval in the United States and Europe.
- Roche has developed a patient-controlled analgesia (PCA) system for PONV management, which delivers a combination of opioids and antiemetic medications through a patient-controlled pump. The PCA system has been shown to be effective in reducing the incidence of PONV and improving patient satisfaction.
Key Companies Profiled
- Acacia Pharma
- Hoffmann-La Roche AG
- Novartis AG
- Ani Pharmaceuticals, Inc
- Camurus AB
- Sanofi S.A.
- Helsinn Holding S.A.
- Eisai Corporation
- Merck and Co.
- GlaxoSmithKline Corporation
Key Segments Profiled in the Postoperative Nausea and Vomiting (PONV) Management Industry Survey
Treatment Type:
- Serotonin Antagonists
- Steroids
- Dopamine Antagonists
- Neurokinin NK-1 Receptor Antagonists
- Non-pharmacological Treatment
Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies and Drug Stores
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
